Pancreatic cancer, specifically driven by the Kirsten rat sarcoma virus gene mutation (KRAS), remains a formidable clinical challenge with limited therapeutic options. The absence of FDA-approved drugs directly targeting KRAS necessitates exploration of novel and more effective treatment strategies. This comprehensive literature review seeks to identify promising therapeutic avenues for pancreatic cancer by evaluating advancements in drug delivery systems. Nab-paclitaxel, an antimitotic agent, exhibits superior pharmacokinetic and bioavailability profiles compared to conventional paclitaxel. Utilizing poly (lactic-co-glycolic acid) (PLGA) nanoparticles as carriers, we investigate the potential of nab-paclitaxel-loaded PLGA nanoparticles to enhance drug delivery and efficacy. Manufactured through the oil-in-water emulsification solvent evaporation method, nab-paclitaxel-loaded PLGA nanoparticles offer a faster half-life and undergo elimination via biliary excretion and metabolism. Notably, these nanoparticles leverage nanoalbumin interactions with cysteine/osteonectin-rich, acidic secreted proteins, resulting in highly selective targeting of pancreatic cancer cells. The findings of this review underscore the potential superiority of nab-paclitaxel-loaded PLGA nanoparticles in terms of pharmacokinetics, pharmacodynamics, and clinical outcomes. Their ability to address the challenges posed by KRAS-driven pancreatic cancer holds promise as a transformative approach in the treatment landscape. In conclusion, this review highlights the evolving landscape of therapeutic options for pancreatic cancer, shedding light on nab-paclitaxel-loaded PLGA nanoparticles as a potent and selective intervention. Further clinical validation and exploration of this innovative strategy are warranted to advance the management of this devastating disease.